MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by StockNews.com

MiMedx Group (NASDAQ:MDXG) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st. Craig Hallum decreased their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Price Performance

MiMedx Group stock opened at $7.44 on Friday. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $9.27. The stock has a fifty day moving average of $6.10 and a 200-day moving average of $6.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market capitalization of $1.09 billion, a P/E ratio of 13.53 and a beta of 1.94.

Institutional Investors Weigh In On MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Caxton Associates LP bought a new stake in shares of MiMedx Group during the 1st quarter valued at about $1,018,000. Victory Capital Management Inc. boosted its position in shares of MiMedx Group by 909.0% during the 2nd quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock valued at $959,000 after purchasing an additional 124,727 shares in the last quarter. Isthmus Partners LLC boosted its position in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of MiMedx Group by 13.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock valued at $254,000 after purchasing an additional 3,806 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of MiMedx Group by 47.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after purchasing an additional 413,443 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.